Summaries of the Section H (HML) update

Each month we issue a summary of the HML update. The table on this page gives a preview of the upcoming changes.

The table on this page gives a preview of the upcoming changes that will be announced in next month’s Section H of the Pharmaceutical Schedule.

The changes will be published in the Online HML(external link) around the 23^rd of this month and are effective from next month.

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz.

16 April 2026 - preview of changes for May 2026

Pharmaceutical	Change
Adrenaline (DBL Adrenaline) inj 1 in 10,000, 10 ml ampoule	amended brand name
Biotin inj 5 mg per ml, 1 ml ampoule	new listing
Candesartan cilexetil (Candesartan Viatris)	new listing Tab 4 mg (p’code 2726440) Tab 8 mg (p’code 2726459) Tab 16 mg (p’code 2726467) Tab 32 mg (p’code 2726475)
Candesartan cilexetil (Candesartan Viatris Sante) tab 8 mg, 16 mg and 32 mg	delisted 1 May 2026
Cefalexin (Cefalexin Sandoz) grans for oral liq 25 mg per ml	new listing and addition of PSS (p’code 2714078)
Cefalexin (Cefalexin Sandoz) grans for oral liq 50 mg per ml	price decrease and addition of PSS
Cefalexin (Flynn) grans for oral liq 25 mg per ml and 50 mg per ml	to be delisted 1 December 2026
Daptomycin inj 500 mg vial	Brand change Daptomycin-AFT – new listing and addition of PSS (p’code 2721899) Daptomycin Dr Reddy’s to be delisted 1 October 2026
Doxorubicin hydrochloride (Doxorubicin Ebewe) inj 2 mg per ml, 25 ml vial and inj 2 mg per ml, 100 ml vial	price increase
Epirubicin hydrochloride (Epirubicin Ebewe) inj 2 mg per ml, 100 ml vial	delisting devoked
Epirubicin hydrochloride (Epirubicin Ebewe) inj 2 mg per ml, 25 ml vial and inj 2 mg per ml, 100 ml vial	price increase
Ezetimibe with simvastatin (Vytorin) tab 10 mg with simvastatin 40 mg	new listing (p’code 2727722)
Fludarabine phosphate (Fludarabine Ebewe) inj 50 mg vial	price increase
Hydralazine hydrochloride (Hydrapres) inj 20 mg ampoule	new listing (p’code 2728176)
Ibrutinib (Imbruvica) tab 140 mg and tab 420 mg	amended restriction criteria
Icatibant inj 10 mg per ml, 3 ml prefilled syringe	Brand change Icatibant Lupin – new listing and addition of PSS (p’code 2720531) Firazyr to be delisted 1 October 2026
Imiquimod (Aldara) crm 5%, 250 mg sachet	new listing (p’code 2728087)
Iohexol (Omnipaque) inj 300 mg per ml (iodine equivalent), 20 ml bottle	to be delisted 1 October 2026
Ipilimumab (Yervoy) inj 5 mg per ml, 10 ml vial and inj 5 mg per ml, 40 ml vial	amended restriction criteria
Letermovir (Prevymis) tab 240 mg	new listing (p’code 2630605)
Magnesium oxide with magnesium aspartate, magnesium amino acid chelate and magnesium citrate cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (345 mg elemental magnesium)	new listing
Magnesium oxide with magnesium aspartate, magnesium amino acid chelate and magnesium citrate cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium)	to be delisted 1 November 2026
Mitozantrone (Mitozantrone Ebewe) inj 2 mg per ml, 10 ml vial	price increase
Montelukast (Relonchem) tab 5 mg	new listing (p’code 2728079)
Nitrofurantoin (Nitrofurantoin Clinect) tab 50 mg	new listing (p’code 2723670)
Nitrofurantoin (Nifuran) tab 50 mg and 100 mg	to be delisted 1 November 2026
Nivolumab (Opdivo) inj 10 mg per ml, 4 ml vial and inj 10 mg per ml, 10 ml vial	amended restriction criteria
Obinutuzumab (Gazyva) inj 25 mg per ml, 40 ml vial	amended restriction criteria
Olanzapine (Olanzapine ODT Viatris)	new listing Tab orodispersible 5 mg (p’code 2726335) Tab orodispersible 10 mg (p’code 2726327)
Palivizumab (Synagis) inj 100 mg per ml, 1 ml vial	amended restriction criteria
Pazopanib (Pazopanib ADVZ) tab 200 mg	new listing (p’code 2726645)
Pirfenidone (Pirfenidone Sandoz) tab 267 mg and 801 mg	Brand change new listing and addition of PSS Tab 267 mg (p’code 2715961) Tab 801 mg (p’code 2715988) Esbriet to be delisted 1 October 2026
Plerixafor inj 20 mg per ml, 1.2 ml vial	Brand change Plerixafor-AFT – new listing and addition of PSS (p’code 2724685) Mozobil to be delisted 1 October 2026
Polyethylene glycol 400 and propylene glycol (Systane Unit Dose) eye drops 0.4% with propylene glycol 0.3% preservative free, single dose	new listing for new pack size (28) (p’code 2718634)
Polyethylene glycol 400 and propylene glycol (Systane Unit Dose) eye drops 0.4% with propylene glycol 0.3% preservative free, single dose	30 pack to be delisted 1 November 2026 (p’code 2640120)
Ramipril	new listing Tab 1.25 mg (Ramipril Viatris) (p’code 2728192) Tab 5 mg (Ramipril Mylan Generics) (p’code 2727854) Tab 10 mg (Ramipril Mylan Generics) (p’code 2727862)
Rituximab (Riximyo) inj 10 mg per ml, 10 ml vial and inj 10 mg per ml, 50 ml vial	amended restriction criteria
Salbutamol with ipratropium bromide (Combiprasal) nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule	new listing (p’code 2729512)
Venetoclax (Venclexta) tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg, tab 10 mg, tab 50 mg and tab 100 mg	amended restriction criteria
Venetoclax (Venclexta) tab 50 mg	new listing (p’code 2696754)
Zoledronic acid (Zoledronic Acid Injection Mylan) inj 4 mg per 5 ml, vial	to be delisted 1 November 2026

Find previous months' summaries